GLP-1 Spotlight: Navigating Coverage, Costs, and Clinical Outcomes
Join us for an in-depth exploration of one of the most impactful developments in prescription drug benefits: GLP-1 medications for type 2 diabetes and obesity management. Drawing from PSG’s 2025 Trends in Drug Benefit Design Report, this webinar provides essential insights for benefits professionals navigating the complex landscape of GLP-1 coverage decisions.
The rapid adoption of GLP-1 medications has created unprecedented challenges for plans as they balance clinical effectiveness with financial sustainability. Our experts will present the latest data on coverage trends, affordability concerns, and innovative cost containment strategies being implemented across the industry.
Watch the Recording
What You’ll Learn
- Current payer perspectives on GLP-1 coverage for obesity treatment and type 2 diabetes management
- Emerging affordability thresholds and price sensitivity among plans
- Strategies for addressing off-label type 2 diabetes GLP-1 use and its financial impact
- Approaches to prior authorization protocols and BMI requirements for obesity GLP-1s
- The role of weight management vendors in comprehensive obesity GLP-1 coverage strategies
- Market insights on compounded GLP-1 products and their place in benefit design
Attendees will gain actionable strategies and insights to optimize their pharmacy benefit design for these high-impact medications in 2025 and beyond.
Expert insight from our panelists:
Morgan Lee, PhD, MPH, CPH
Vice President, Research & Marketing
Scott Halperin, PharmD
Vice President, Employer Pharmacy Benefit Consulting
Steve Altenburger, PharmD
Senior Pharmacy Benefit Consultant